Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DEXCOM INC Director's Dealing 2014

Feb 12, 2014

30198_dirs_2014-02-12_bc67ca26-befd-4d77-8d8b-42b8ddcabe69.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2014-02-10

Reporting Person: VALDES JORGE A (CTO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2014-02-10 Common Stock M 16000.0 $3.19 Acquired 160853 Direct
2014-02-10 Common Stock S 16000.0 $38.0305 Disposed 144853 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2014-02-10 Non-Qualified Stock Option (right to buy) $ M 16000.0 Disposed 2018-12-11 Common Stock (16000) Direct

Footnotes

F1: On November 15, 2013, Mr. Valdes adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Valdes. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2: This transaction was executed in multiple trades at prices ranging from $37.75 to $38.32. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.

F3: Included in this number are 119,429 unvested restricted stock units, 71,621 of which were granted on March 11, 2013 and shall vest through March 11, 2016, 35,811 of which were granted on March 8, 2012 and shall vest through March 8, 2015 and 11,997 of which were granted on March 8, 2011 and shall vest through March 8, 2014.

F4: Conversion or exercise price of derivative security is $3.19.